Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

BACKGROUND: Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug Administrration–approved treatment for type 2 diabetes mellitus (T2DM). A 3070-subject randomized trial demonstrated a significant, 40% reduction in relative ri...

Full description

Saved in:
Bibliographic Details
Main Authors: Gaziano, J. Michael, Cincotta, Anthony H., Vinik, Aaron, Blonde, Lawrence, Bohannon, Nancy, Scranton, Richard
Format: Artigo
Language:Inglês
Published: Blackwell Publishing Ltd 2012
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3541616/
https://ncbi.nlm.nih.gov/pubmed/23316290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.112.002279
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items